Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain.

摘要: Abstract Context Methadone is an important drug in the management of both cancer-related and non–cancer-related pain main pharmacologic agent used treatment opioid addiction. Unexpected hypoglycemia has been observed patients receiving methadone, prompting a more detailed investigation. Objectives To evaluate incidence cohort inpatients methadone versus other opioids including fentanyl, hydromorphone, morphine. Methods Retrospective observational tertiary cancer center admitted for than 48 hours from November 1, 2011 to October 30, 2013. The outcomes were lowest measured daily blood glucose (in mg/dL) (defined as glucose  Results Of 641 eligible during study period who received at least one dose admission, multivariable logistic regression showed significant associations between doses greater 40 mg oral equivalents per day or with patient-controlled analgesia use. A dose-response relationship was observed, odds ratio 3.1 (95% confidence interval 2.5, 3.6) when 80 mg/day used. No evidence increased risk curve seen opioids. Conclusion taking day. When starting 40 mg/day, we recommend monitoring.